Study proves the effectiveness of Parkinson’s drug apomorphine

News

Author: Parkinson's Life editorsPublished: 11 May 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Results from the 12-week TOLEDO study – which tested the effectiveness of APO-go®/MOVAPO® (apomorphine) on Parkinson’s patients whose symptoms could not be controlled with standard therapies – showed that patients treated with the infusion had a significantly greater improvement in ‘off’ time, compared with those taking the placebo.

The reduction in ‘off’ time was achieved without an increase in dyskinesias and was reflected in the patients’ own assessment of the overall treatment effect.

The results were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, US, last month.

Professor Katzenschlager, lead investigator of the TOLEDO study, said: “TOLEDO provides the high-level evidence we needed for the efficacy and tolerability of apomorphine infusion in patients who are still experiencing debilitating treatment response fluctuations despite receiving optimised treatment, and confirms the clinical experience of those who have used apomorphine infusion for many years.”

Go Back

Share this story

Comments


Related articles


New to Parkinson's video lead

Resources & Tools

VIDEO: “No one with Parkinson’s should feel alone”

Video: Parkinson’s communities share experiences of the condition

READ MORE
Harry Styles' mum wing walks for Parkinson's

Global update

Harry Styles’ mum Anne Twist wing walks for Parkinson’s

The campaign has raised over £10,000 for Parkinson’s disease so far

READ MORE
PL_John L Lehr PDF CEO lead

Interviews

John Lehr: “I’m inspired by the persistent hope of those living with Parkinson’s”

PDF CEO unveils plans for organisation’s 60th anniversary year

READ MORE